表紙
市場調查報告書
商品編碼
1035789

阿爾茨海默病市場(第 2 版):按治療類型、適應症、按地區,2021-2030

Alzheimer's Disease Market (2nd edition) by Type of Treatment (Symptomatic and Disease Modifying), Symptomatic Indications (Dementia, Insomnia and Other Psychological Symptoms) and Geography (North America, Europe and Asia-Pacific), 2021-2030

出版日期: | 出版商: Roots Analysis | 英文 150 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

視覺

概述

阿爾茨海默病佔癡呆症的 60-70%,在美國被稱為第六大死因。目前,超過 600 萬美國人患有各個年齡段的阿爾茨海默病,預計到 2050 年這一數字將達到約 1300 萬。到2020年,與阿爾茨海默病相關的醫療費用估計約為3050億美元。

本報告探討了阿爾茨海默病市場,並提供了市場概況,以及按治療類型、適應症、地區和進入市場的公司概況的趨勢。

目錄

第一章前言

  • 調查範圍
  • 調查方法
  • 重要問題得到解答
  • 章節概述

第 2 章執行摘要

第 3 章介紹

  • 阿爾茨海默病概述
    • 阿爾茨海默病:體徵和症狀
    • 阿爾茨海默病的病因
    • 阿爾茨海默病分期
  • 阿爾茨海默病管理:美國國立衛生研究院開展的一項計劃
  • 阿爾茨海默病的管理
  • 阿爾茨海默病的數字生物標誌物
    • 數字生物標誌物在阿爾茨海默病中的可能性
    • 阿爾茨海默病可穿戴/移動設備傳感器或數字傳感

第 4 章管道審查:非處方藥和臨床階段藥物

  • 分析研究方法及主要參數
  • 阿爾茨海默病治療:商業和開發管道
    • 開發階段分析
    • 按分子類型分析
    • 按目標階段分析
    • 按治療類型分析
    • 作用機制分析
    • 管理渠道分析
    • 按給藥頻率分析
    • 按治療類型分析
    • 按到達診所的路線分析
    • 網格分析:發展階段、臨床路徑、治療類型分佈
  • 阿爾茨海默病治療:開發商名單
    • 按成立年份分析
    • 按地理位置分析公司規模和總部
    • 主要參與者:按治療次數分析
    • 區域分析

第五章公司簡介

  • 艾伯維
    • 公司簡介
    • 財務信息
    • 產品組合
    • 近期趨勢和未來前景
  • AC 免疫
    • 公司簡介
    • 財務信息
    • 產品組合
    • 近期趨勢和未來前景
  • 百健
    • 公司簡介
    • 財務信息
    • 產品組合
    • 近期趨勢和未來前景
  • 衛材
    • 公司簡介
    • 財務信息
    • 產品組合
    • 近期趨勢和未來前景
  • 禮來公司
    • 公司簡介
    • 財務信息
    • 產品組合
    • 近期趨勢和未來前景
  • 葛蘭素史克
    • 公司簡介
    • 財務信息
    • 產品組合
    • 近期趨勢和未來前景
  • 獅鷲
    • 公司簡介
    • 財務信息
    • 產品組合
    • 近期趨勢和未來前景
  • 楊森製藥
    • 公司簡介
    • 財務信息
    • 產品組合
    • 近期趨勢和未來前景
  • Neurom 製藥
    • 公司簡介
    • 財務信息
    • 產品組合
    • 近期趨勢和未來前景
  • 諾華
    • 公司簡介
    • 財務信息
    • 產品組合
    • 近期趨勢和未來前景
  • 諾和諾德
    • 公司簡介
    • 財務信息
    • 產品組合
    • 近期趨勢和未來前景
  • 羅氏
    • 公司簡介
    • 財務信息
    • 產品組合
    • 近期趨勢和未來前景
  • 武田製藥
    • 公司簡介
    • 財務信息
    • 產品組合
    • 近期趨勢和未來前景

第 6 章案例研究:審查毒品

  • 章節概述
  • 阿爾茨海默病治療:停產藥物清單
  • 阿爾茨海默病治療:中止臨床試驗清單
  • 結論

第七章出版物分析

  • 分析研究方法及主要參數
  • 阿爾茨海默病:出版物清單
  • 按發行年份分析
  • 按主要優先領域進行分析
  • 研究標題詞雲
  • 頂級期刊:按出版物數量分析
  • 第一作者:按出版物數量分析

第 8 章夥伴關係和協作

  • 分析研究方法及主要參數
  • 合作模式
  • 阿爾茨海默病:夥伴關係和合作清單

第九章融資與投資分析

  • 分析研究方法及主要參數
  • 資金類型
  • 融資與投資分析

第 10 章贈款分析

  • 分析研究方法及主要參數
  • 阿爾茨海默病:學術資助清單

第11章臨床試驗分析

  • 分析研究方法及主要參數
  • 阿爾茨海默病:臨床試驗分析

第十二章專利分析

  • 分析研究方法及主要參數
  • 阿爾茨海默病:專利分析

第十三章非藥物干預與診斷

  • 阿爾茨海默病的非藥物干預

第14章市場規模和機會分析

  • 預測性研究方法和關鍵假設
  • 2021-2030 年全球阿爾茨海默病市場
  • 2021-2030 年全球阿爾茨海默病市場:按治療類型分佈
  • 2021-2030 年全球阿爾茨海默病市場:按目標疾病適應症類型分佈
  • 2021-2030 年全球阿爾茨海默病市場:區域分佈
    • 北美
    • 歐洲
    • 亞太地區

第 15 章結論

第 16 章高管洞察力

第17章附錄1:匯總數據

第 18 章附錄 2:公司和組織名單

目錄

VISUALS

Overview:

Alzheimer's disease is a progressive neurological disorder characterized by the death of brain cells, eventually leading to memory loss, cognitive dysfunction and dementia. Accounting for 60-70% cases of dementia, Alzheimer's disease is known to be the sixth leading cause of death in the US. Presently, more than 6 million Americans of all ages are living with Alzheimer's and this number is projected to reach around 13 million by 2050. In 2020, the healthcare burden associated with the disease was estimated to be around USD 305 billion. Given the socioeconomic burden associated with Alzheimer's, pharmaceutical players have been on the lookout for reliable diagnostic tests and effective treatment alternatives that can slow the progression of this disease. However, not many drugs could make their way to the market and majority of the existing therapeutic approaches have proven ineffective in the treatment of Alzheimer's disease and its related symptoms.

Recently, in June 2021, the FDA granted accelerated approval for the first disease modifying therapy, Aduhelm™ (Aducanumab), developed by Biogen, for the treatment of Alzheimer's disease. The approval of this amyloid beta-directed antibody has sparked a ray of hope for other players which are seeking approval for similar therapies. Further, multiple partnerships have been forged by various established players and start-ups in this domain in order to expand their research efforts and respective product portfolios. In addition, venture capital and other strategic investors are providing the necessary financial support to the research initiatives being undertaken by start-ups. Given the ongoing efforts aimed at finding effective and potential therapeutic cure, we are led to believe that the Alzheimer's disease market is likely to witness healthy growth in the coming years.

Scope of the Report:

The "Alzheimer's Disease Market (2nd Edition) by Type of Treatment (Symptomatic and Disease Modifying), Symptomatic Indications (Dementia, Insomnia and Other Psychological Symptoms) and Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2021-2030" report features an extensive study on the current landscape of the marketed, clinical and preclinical molecules available / being developed for the treatment of Alzheimer's disease, offering an informed opinion on the likely evolution of the market, till 2030. The study underlines an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report features:

  • A detailed review of the current market landscape of drugs developed for the treatment of Alzheimer's, including analyses based on several relevant parameters, such as current status of development (marketed, clinical and pre-clinical), phase of development (phase IV, phase III, phase II/III, phase II, phase I/II and phase I) of lead candidates, type of biologic (antibodies, peptides, cell and gene therapy, protein and vaccines), target disease stage (early stage, mild stage, mild to moderate stage and moderate to severe stage), type of treatment (symptomatic treatment, disease modifying treatment and both), mechanism of action (inhibitor, activator and modulator), route of administration (oral, intravenous, subcutaneous and others), dosing frequency (single dose, daily, twice daily, thrice daily, weekly, biweekly, monthly) type of therapy (monotherapy and combination therapy) and path to clinic (dedicated, repositioned and repurposed). Additionally, the report provides information on drug developer(s) involved in the domain, along with analyses based on a number of relevant parameters, such as year of establishment, company size and geographical location of headquarters.
  • A detailed analysis of completed, ongoing and planned clinical trials of the drugs for the treatment of Alzheimer's disease and its related symptoms, on the basis of several relevant parameters, such as trial status, trial registration year, type of sponsor / collaborator, type of study design, enrolled patient population, age category, leading industry sponsors / collaborators (in terms of number of trials conducted)and regional distribution of trials.
  • Elaborate profiles of the key players involved in the development of therapeutics for Alzheimer's disease. Each profile features a brief overview of the company, its financial information, details on its product portfolio, and recent developments and an informed future outlook.
  • An in-depth analysis of grants that have been awarded to various research institutes for projects related to Alzheimer's disease, in the period between 2017 and 2021, on the basis of important parameters, such as year of grant award, grant amount awarded, administering institute center, support period, type of grant application, grant activity code, emerging focus area, purpose of grant award, type of recent organization, popular NIH department and prominent program officers.
  • An analysis of the partnerships established between various stakeholders in this domain, during the period 2017-2021, covering product development and commercialization agreements, R&D agreements, technology / product licensing agreements, other licensing agreements, mergers and acquisitions, clinical trial agreements and other relevant types of deals.
  • A review of the funding and investments made in the domain, in the period between 2017 and 2021, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development. The analysis has been done on the basis of several parameters, such as number of funding instances, amount invested, type of funding, leading players and investors, and geographical analysis.
  • A detailed assessment of discontinued drugs and terminated trials, providing information on the year of discontinuation, reason(s) for discontinuation, phase of discontinuation, mechanism of action of the terminated drugs, type of indication, reason for termination, affiliated stakeholders.
  • A detailed review of around 20,000 peer-reviewed, scientific articles related to research on Alzheimer's disease, which have been published between 2017 and June 2021, including analysis based on parameters, such as year of publication, key focus area, type of molecule, popular keywords, and key journals (in terms of number of articles published in this domain and impact factor of the journal).
  • An in-depth analysis of the patents related to Alzheimer's disease, filed / granted since 2017, based on various parameters, such as patent publication year, geographical location / patent jurisdiction, CPC symbols, emerging focus areas, and type of applicant, and leading players (by number of patents). In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.

One of the key objectives of the report was to estimate the existing market size and the future growth opportunities for therapies being developed for the treatment of Alzheimer's disease, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption rates and the selling price / likely selling price of therapies for the disease, we have developed informed estimates on the evolution of the market for the period 2021-2030 The report also features the likely distribution of the current and forecasted opportunity across [A] type of treatment (symptomatic and disease modifying treatment) [B] symptomatic indications (dementia, insomnia and other psychological symptoms) and [C] key geographical regions (North America, Europe and Asia-Pacific). To account for the future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, portraying different tracks of the anticipated industry's growth. The opinions and insights presented in this study were influenced by inputs solicited via a comprehensive survey and discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Kenneth Moch (President and Chief Executive Officer, Cognition Therapeutics)
  • Mathias Schmidt (Chief Executive Officer, ArmaGen)
  • Ram Bhatt (Chief Executive Officer, Chairman and Founder, ICB International)

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the leading industry players involved in the Alzheimer's disease industry?
  • Which geographies are the most active in conducting clinical trials on therapies for Alzheimer's disease?
  • Which are the leading funding organizations providing grants in the Alzheimer's disease industry?
  • Which partnership models are commonly adopted by industry stakeholders in the Alzheimer's disease industry?
  • How is the current and future market opportunity, related to Alzheimer's disease, likely to be distributed across key market segments?

Chapter Outlines:

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the Alzheimer's disease market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to Alzheimer's disease and its associated symptoms. The chapter features a detailed discussion on the causes of disease, stages of disease progression, factors influencing the onset and progression of the disease, and the different pharmacological and non-pharmacological interventions intended for the treatment of this condition. The chapter includes information on the epidemiology of the disease, highlighting the diverse initiatives / programs led by the National Institutes of Health (NIH). Additionally, the chapter provides an overview of digital biomarkers and their use in the management of Alzheimer's disease.

Chapter 4 provides detailed review of the current market landscape of drugs developed for the treatment of Alzheimer's, including analyses based on several relevant parameters, such as current status of development (marketed, clinical and pre-clinical), phase of development (phase IV, phase III, phase II/III, phase II, phase I/II and phase I) of lead candidates, type of biologic (antibodies, peptides, cell and gene therapy, protein and vaccines), target disease stage (early stage, mild stage, mild to moderate stage and moderate to severe stage), type of treatment (symptomatic treatment, disease modifying treatment and both), mechanism of action (inhibitor, activator and modulator), route of administration (oral, intravenous, subcutaneous and others), dosing frequency (single dose, daily, twice daily, thrice daily, weekly, biweekly, monthly) type of therapy (monotherapy and combination therapy) and path to clinic (dedicated, repositioned and repurposed). Additionally, the report provides information on drug developer(s) involved in the domain, along with analyses based on a number of relevant parameters, such as year of establishment, company size and geographical location of headquarters.

Chapter 5 features detailed profiles of the key stakeholders involved in the development of therapeutics for Alzheimer's disease. Each profile features a brief overview of the company, its financial information, details on its product portfolio, and recent developments and an informed future outlook.

Chapter 6 features a detailed assessment of over 110 discontinued drugs and terminated trials, providing information on the year of discontinuation, reason(s) for discontinuation, phase of discontinuation, mechanism of action of the terminated drugs, type of indication, reason for termination, affiliated stakeholders. In addition, the chapter presents a list of about 180 terminated clinical trials along with information on the year of termination and the key geographies across which these trials were being conducted.

Chapter 7 provides a detailed review of around 20,000 peer-reviewed, scientific articles related to research on Alzheimer's disease, which have been published between 2017 and June 2021, including analysis based on parameters, such as year of publication, key focus area, type of molecule, popular keywords, and key journals (in terms of number of articles published in this domain and impact factor of the journal).

Chapter 8 features an analysis of the partnerships established between various stakeholders in this domain, during the period 2017-2021, covering product development and commercialization agreements, R&D agreements, technology / product licensing agreements, other licensing agreements, mergers and acquisitions, clinical trial agreements and other relevant types of deals.

Chapter 9 presents a review of the funding and investments made in the domain, in the period between 2017 and 2021, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development. The analysis has been done on the basis of several parameters, such as number of funding instances, amount invested, type of funding, leading players and investors, and geographical analysis.

Chapter 10 provides an in-depth analysis of analysis of more than 5,600 grants that have been awarded to various research institutes for projects related to Alzheimer's disease, in the period between 2017 and 2021, on the basis of important parameters, such as year of grant award, grant amount awarded, administering institute center, support period, type of grant application, grant activity code, emerging focus area, purpose of grant award, type of recent organization, popular NIH department and prominent program officers.

Chapter 11 provides a detailed analysis of more than 2,000 completed and ongoing clinical studies of therapies being developed for the treatment of Alzheimer's, based on parameters, such as current trial status, trial registration year, phase of development, study design, leading industry sponsors (in terms of number of trials conducted), study focus, target indication(s), focus areas, target therapeutic area(s), enrolled patient population and regional distribution of trials.

Chapter 12 provides an overview of the various patents that have been filed / granted, since 2017, based on various parameters, such as publication year, geography, CPC symbols, emerging focus areas, type of applicant and leading industry players (in terms of number of patents filed). In addition, the chapter also features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.

Chapter 13 provides information on the various non-pharmacological interventions, including cognition / emotion-oriented therapies, sensory simulation therapies and other psychological interventions. The chapter presents a list of companies that offer such solutions, providing information on the devices / products and their mechanisms of action / working principles. In addition, the chapter includes a list of novel diagnostic techniques, which are claimed to be capable of assisting in timely diagnosis.

Chapter 14 includes an insightful market forecast analysis, highlighting growth opportunities of Alzheimer's disease market till the year 2030. In addition, we have provided inputs on the likely distribution of the market opportunity based on different type of treatment (symptomatic and disease modifying treatment), symptomatic indications (dementia, insomnia and other psychological symptoms) and key geographical regions (North America, Europe and Asia-Pacific). To account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

Chapter 15 is a summary of the overall report, presenting the insights on the contemporary market trends and the likely evolution of the Alzheimer's disease market.

Chapter 16 is a collection of interview transcripts of the discussions held with key stakeholders in this industry. Is a collection of interview transcripts of the discussions held with key stakeholders in this industry. In this chapter, we have presented the details of interviews held with (in alphabetical order) Kenneth Moch (President and Chief Executive Officer, Cognition Therapeutics), Mathias Schmidt, (Chief Executive Officer, ArmaGen) and Ram Bhatt (Chief Executive Officer, Chairman and Founder, ICB International).

Chapter 17 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 18 is an appendix, which contains the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. An Overview of Alzheimer's Disease
    • 3.1.1. Alzheimer's Disease: Signs and Symptoms
    • 3.1.2. Causes of Alzheimer's Disease
    • 3.1.3. Stages of Alzheimer's Disease
  • 3.2. Alzheimer's Disease Management: Programs Undertaken by The National Institutes of Health
  • 3.3. Alzheimer's Disease Management
  • 3.4. Digital Biomarkers in Alzheimer's Disease
    • 3.4.1. Potential of Digital Biomarkers in Alzheimer's Disease
    • 3.4.2. Sensors or Digital Senses in Wearable / Mobile Devices for Alzheimer's Disease

4. PIPELINE REVIEW: MARKETED AND CLINICAL- STAGE DRUGS

  • 4.1. Analysis Methodology and Key Parameters
  • 4.2. Alzheimer's Disease Therapies: Marketed and Development Pipeline
    • 4.2.1. Analysis by Phase of Development
    • 4.2.2. Analysis by Type of Molecule
    • 4.2.3. Analysis by Target Disease Stage
    • 4.2.4. Analysis by Type of Treatment
    • 4.2.5. Analysis by Mechanism of Action
    • 4.2.6. Analysis by Route of Administration
    • 4.2.7. Analysis by Dosing Frequency
    • 4.2.8. Analysis by Type of Therapy
    • 4.2.9. Analysis by Path to Clinic
    • 4.2.10. Grid Analysis: Distribution by Phase of Development, Path to Clinic and Type of Therapy
  • 4.4. Alzheimer's Disease Therapies: List of Developers
    • 4.4.1. Analysis by Year of Establishment
    • 4.4.2. Analysis by Company Size and Geographical Location of Headquarters
    • 4.4.3. Leading Players: Analysis by Number of Therapies
    • 4.4.4. Analysis by Geography

5. COMPANY PROFILES

  • 5.1. AbbVie
    • 5.1.1. Company Overview
    • 5.1.2. Financial Information
    • 5.1.3. Product Portfolio
    • 5.1.4. Recent Developments and Future Outlook
  • 5.2. AC Immune
    • 5.2.1. Company Overview
    • 5.2.2. Financial Information
    • 5.2.3. Product Portfolio
    • 5.2.4. Recent Developments and Future Outlook
  • 5.3. Biogen
    • 5.3.1. Company Overview
    • 5.3.2. Financial Information
    • 5.3.3. Product Portfolio
    • 5.3.4. Recent Developments and Future Outlook
  • 5.4. Eisai
    • 5.4.1. Company Overview
    • 5.4.2. Financial Information
    • 5.4.3. Product Portfolio
    • 5.4.4. Recent Developments and Future Outlook
  • 5.5. Eli Lilly and Company
    • 5.5.1. Company Overview
    • 5.5.2. Financial Information
    • 5.5.3. Product Portfolio
    • 5.5.4. Recent Developments and Future Outlook
  • 5.6. GlaxoSmithKline
    • 5.6.1. Company Overview
    • 5.6.2. Financial Information
    • 5.6.3. Product Portfolio
    • 5.6.4. Recent Developments and Future Outlook
  • 5.7. Grifols
    • 5.7.1. Company Overview
    • 5.7.2. Financial Information
    • 5.7.3. Product Portfolio
    • 5.7.4. Recent Developments and Future Outlook
  • 5.8. Janssen Pharmaceutical
    • 5.8.1. Company Overview
    • 5.8.2. Financial Information
    • 5.8.3. Product Portfolio
    • 5.8.4. Recent Developments and Future Outlook
  • 5.9. Neurim Pharmaceuticals
    • 5.9.1. Company Overview
    • 5.9.2. Financial Information
    • 5.9.3. Product Portfolio
    • 5.9.4. Recent Developments and Future Outlook
  • 5.10. Novartis
    • 5.10.1. Company Overview
    • 5.10.2. Financial Information
    • 5.10.3. Product Portfolio
    • 5.10.4. Recent Developments and Future Outlook
  • 5.11. Novo Nordisk
    • 5.11.1. Company Overview
    • 5.11.2. Financial Information
    • 5.11.3. Product Portfolio
    • 5.11.4. Recent Developments and Future Outlook
  • 5.12. Roche
    • 5.12.1. Company Overview
    • 5.12.2. Financial Information
    • 5.12.3. Product Portfolio
    • 5.12.4. Recent Developments and Future Outlook
  • 5.13. Takeda Pharmaceutical
    • 5.13.1. Company Overview
    • 5.13.2. Financial Information
    • 5.13.3. Product Portfolio
    • 5.13.4. Recent Developments and Future Outlook

6. CASE STUDY: TERMINATED DRUGS

  • 6.1. Chapter Overview
  • 6.2. Alzheimer's Disease Therapies: List of Terminated Drugs
    • 6.2.1. Analysis by Year of Discontinuation
    • 6.2.2. Analysis by Phase of Discontinuation
    • 6.2.3. Analysis by Mechanism of Action
    • 6.2.4. Analysis by Type of Indication
    • 6.2.5. Analysis by Reason for Termination
    • 6.2.6. Analysis by Affiliated Stakeholders
  • 6.3. Alzheimer's Disease Therapies: List of Terminated Clinical Trials
    • 6.3.1. Distribution by Study Start Year and Year of Termination of Clinical Trials
    • 6.3.2. Analysis by Location of Trials
  • 6.4. Concluding Remarks

7. PUBLICATION ANALYSIS

  • 7.1. Analysis Methodology and Key Parameters
  • 7.2. Alzheimer's Disease: List of Publications
  • 7.3. Analysis by Year of Publication
  • 7.4. Analysis by Key Focus Area
  • 7.5. Word Cloud of Study Titles
  • 7.6. Top Journal: Analysis by Number of Publications
  • 7.6. Top Author: Analysis by Number of Publications

8. PARTNERSHIPS AND COLLABORATIONS

  • 8.1. Analysis Methodology and Key Parameters
  • 8.2. Partnership Models
  • 8.3. Alzheimer's Disease: List of Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Analysis by Type of Partnership and Focus Area of Partnership
    • 8.3.4. Analysis by Type of Partnership and Type of Molecule
    • 8.3.5. Most Active Players: Analysis by Number of Partnerships
    • 8.3.6. Regional Analysis
    • 8.3.7. Intercontinental and Intracontinental Agreements

9. FUNDING AND INVESTMENT ANALYSIS

  • 9.1. Analysis Methodology and Key Parameters
  • 9.2. Types of Funding
  • 9.3. Funding and Investment Analysis
    • 9.3.1. Analysis by Year of Investment
    • 9.3.2. Analysis by Amount Invested
    • 9.3.3. Analysis by Type of Funding
    • 9.3.4 Analysis by Amount Invested Across Different Types of Molecules
    • 9.3.5 Analysis by Amount Invested Across Different Types of Mechanism of Action
    • 9.3.6. Regional Analysis by Amount Invested
    • 9.3.7. Most Active Players: Analysis by Number of Funding Instances
    • 9.3.8. Most Active Investors: Analysis by Amount Funded

10. GRANT ANALYSIS

  • 10.1. Analysis Methodology and Key Parameters
  • 10.2. Alzheimer's Disease: List of Academic Grants
    • 10.2.1. Analysis by Year of Grant Award
    • 10.2.2. Analysis by Grant Amount Awarded
    • 10.2.3. Analysis by Administering Institute Center
    • 10.2.4. Analysis by Support Period
    • 10.2.5. Analysis by Administering Institute Center and Support Year
    • 10.2.6. Analysis by Type of Grant Application
    • 10.2.7. Analysis by Grant Activity Code
    • 10.2.8. Word Cloud of Study Titles
    • 10.2.9. Analysis by Purpose of Grant Award
    • 10.2.10. Analysis by Type of Recipient Organization
    • 10.2.11. Popular NIH Departments: Analysis by Number of Grants
    • 10.2.12. Prominent Program Officers: Analysis by Number of Grants

11. CLINICAL TRIAL ANALYSIS

  • 11.1. Analysis Methodology and Key Parameters
  • 11.2. Alzheimer's Disease: Clinical Trial Analysis
    • 11.3.1. Analysis by Trial Status
    • 11.3.2. Analysis by Trial Registration Year
    • 11.3.3. Analysis by Type of Sponsor / Collaborator
    • 11.3.3. Analysis by Type of Study Design
    • 11.3.4. Analysis by Registration Year and Type of Study
    • 11.3.5. Analysis by Patient Enrollment
    • 11.3.6. Year-wise Trend of Completed and Recruiting Trials
    • 11.3.7. Analysis by Age Category
    • 11.3.8. Word Cloud of Study Titles
    • 11.3.9. Most Active Industry Players: Analysis by Number of Registered Trials
    • 11.3.10. Most Active Non- Industry Players: Analysis by Number of Registered Trials
    • 11.3.11. Analysis by Trial Location
    • 11.3.12. Analysis by Trial Status and Geography

12. PATENT ANALYSIS

  • 12.1. Analysis Methodology and Key Parameters
  • 12.2. Alzheimer's Disease: Patent Analysis
    • 12.2.1. Analysis by Patent Application Year
    • 12.2.2. Analysis by Geography
    • 12.2.3. Analysis by CPC Symbols
    • 12.2.4. Word Cloud: Emerging Focus Areas
    • 12.2.5. Analysis by Type of Applicant
    • 12.2.6. Leading Players: Analysis by Number of Patents
    • 12.2.7 Leading Players: Analysis by Number of International Patents
    • 12.2.8. Patent Valuation Analysis

13. NON-PHARMACOLOGICAL INTERVENTIONS AND DIAGNOSTICS

  • 13.1. Non-Pharmacological Interventions for Alzheimer's Disease
    • 13.1.1. Cognition / Emotion-Oriented Interventions
      • 13.1.1.1. Reminiscence Therapy
      • 13.1.1.2. Simulated Presence Therapy
    • 13.1.2. Sensory Stimulation-based Interventions
      • 13.1.2.1. Virtual Reality
      • 13.1.2.2. Music Therapy
      • 13.1.2.3. Light Therapy
      • 13.1.2.4. Aromatherapy
      • 13.1.2.5. Reflexology
    • 13.1.3. Other Psycho-social Interventions
      • 13.1.3.1. Animal-Assisted Therapy

14. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 14.1. Forecast Methodology and Key Assumptions
  • 14.2. Global Alzheimer's Disease Market, 2021-2030
  • 14.3. Global Alzheimer's Disease Market, 2021-2030: Distribution by Type of Treatment
  • 14.4. Global Alzheimer's Disease Market, 2021-2030: Distribution by Type of Target Disease Indication
  • 14.5. Global Alzheimer's Disease Market, 2021-2030: Distribution by Geography
    • 14.5.1. Alzheimer's Disease Market in North America, 2021-2030
      • 14.5.1.1. Alzheimer's Disease Market in North America, 2021-2030: Distribution by Type of Treatment
        • 14.5.1.1.1. Alzheimer's Disease Market in North America, 2021-2030: Distribution by Symptomatic Treatment
          • 14.5.1.1.1.1. Alzheimer's Disease Market in North America, 2021-2030: Share of Dementia in Symptomatic Treatment Market
          • 14.5.1.1.1.2. Alzheimer's Disease Market in North America, 2021-2030: Share of Insomnia in Symptomatic Treatment Market
          • 14.5.1.1.1.3. Alzheimer's Disease Market in North America, 2021-2030: Share of Other Psychological Symptoms in Symptomatic Treatment Market
        • 14.5.1.1.2. Alzheimer's Disease Market in North America, 2021-2030: Distribution by Disease Modifying Treatment
    • 14.5.2. Alzheimer's Disease Market in Europe, 2021-2030
      • 14.5.2.1. Alzheimer's Disease Market in Europe, 2021-2030: Distribution by Type of Treatment
        • 14.5.2.1.1. Alzheimer's Disease Market in Europe, 2021-2030: Distribution by Symptomatic Treatment
          • 14.5.2.1.1.1. Alzheimer's Disease Market in Europe, 2021-2030: Share of Dementia in Symptomatic Treatment Market
          • 14.5.2.1.1.2. Alzheimer's Disease Market in Europe, 2021-2030: Share of Insomnia in Symptomatic Treatment Market
          • 14.5.2.1.1.3. Alzheimer's Disease Market in Europe, 2021-2030: Share of Other Psychological Symptoms in Symptomatic Treatment Market
        • 14.5.2.1.2. Alzheimer's Disease Market in Europe, 2021-2030: Distribution by Disease Modifying Treatment
    • 14.5.3. Alzheimer's Disease Market in Asia-Pacific, 2021-2030
      • 14.5.3.1. Alzheimer's Disease Market in Asia-Pacific, 2021-2030: Distribution by Type of Treatment
        • 14.5.3.1.1. Alzheimer's Disease Market in Asia-Pacific, 2021-2030: Distribution by Symptomatic Treatment
          • 14.5.3.1.1.1. Alzheimer's Disease Market in Asia-Pacific, 2021-2030: Share of Dementia in Symptomatic Treatment Market
          • 14.5.3.1.1.2. Alzheimer's Disease Market in Asia-Pacific, 2021-2030: Share of Insomnia in Symptomatic Treatment Market
          • 14.5.3.1.1.3. Alzheimer's Disease Market in Asia-Pacific, 2021-2030: Share of Other Psychological Symptoms in Symptomatic Treatment Market
        • 14.5.3.1.2. Alzheimer's Disease Market in Asia-Pacific, 2021-2030: Distribution by Disease Modifying Treatment

15. CONCLUDING REMARKS

16. EXECUTIVE INSIGHTS

  • 16.1. Cognition Therapeutics
    • 16.1.1. Company Snapshot
    • 16.1.1. Interview Transcript: Kenneth Moch (President and Chief Executive Officer)
  • 16.2. ArmaGen
    • 16.2.1. Company Snapshot
    • 16.2.2. Interview Transcript: Mathias Schmidt (Chief Executive Officer)
  • 16.2. ICB International
    • 16.2.1. Company Snapshot
    • 16.3.2. Interview Transcript: Ram Bhatt (Chief Executive Officer, Chairman and Founder)

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 3.1. Overview of Alzheimer's Disease
  • Figure 3.2. Alzheimer's Disease: Signs and Symptoms
  • Figure 3.3. Causes of Alzheimer's Disease
  • Figure 3.4. Stages of Alzheimer's Disease
  • Figure 3.5. Alzheimer's Disease Management: Programs Undertaken by The National Institutes of Health
  • Figure 3.6. Alzheimer's Disease Management
  • Figure 3.7. Digital Biomarkers in Alzheimer's Disease
  • Figure 3.8. Potential of Digital Biomarkers in Alzheimer's Disease
  • Figure 3.9. Sensors or Digital Senses in Wearable / Mobile Devices for Alzheimer's Disease
  • Figure 4.1. Marketed and Clinical-Stage Drugs: Distribution by Phase of Development
  • Figure 4.2. Marketed and Clinical-Stage Drugs: Distribution by Type of Molecule
  • Figure 4.3. Marketed and Clinical-Stage Drugs: Distribution by Target Disease Stage
  • Figure 4.4. Marketed and Clinical-Stage Drugs: Distribution by Type of Treatment
  • Figure 4.5. Marketed and Clinical-Stage Drugs: Distribution by Mechanism of Action
  • Figure 4.6. Marketed and Clinical-Stage Drugs: Distribution by Route of Administration
  • Figure 4.7. Marketed and Clinical-Stage Drugs: Distribution by Dosing Frequency
  • Figure 4.8. Marketed and Clinical-Stage Drugs: Distribution by Type of Therapy
  • Figure 4.9. Marketed and Clinical-Stage Drugs: Distribution by Path to Clinic
  • Figure 4.10. Grid Analysis: Distribution by Phase of Development, Path to Clinic and Type of Therapy
  • Figure 4.11. Alzheimer's Disease Therapies: List of Developers
  • Figure 4.12. Alzheimer's Disease Therapy Developers: Distribution by Year of Establishment
  • Figure 4.13. Alzheimer's Disease Therapy Developers: Distribution by Company Size and Geographical Location of Headquarters
  • Figure 4.14. Leading Players: Distribution by Number of Therapies
  • Figure 4.15. Alzheimer's Disease Therapy Developers: Distribution by Geography
  • Figure 5.1. AbbVie: Financial Information
  • Figure 5.2. AC Immune: Financial Information
  • Figure 5.3. Biogen: Financial Information
  • Figure 5.4. Eisai: Financial Information
  • Figure 5.5. Eli Lilly and Company: Financial Information
  • Figure 5.6. GlaxoSmithKline: Financial Information
  • Figure 5.7. Grifols: Financial Information
  • Figure 5.8. Janssen Pharmaceutical: Financial Information
  • Figure 5.9. Neurim Pharmaceuticals: Financial Information
  • Figure 5.10. Novartis: Financial Information
  • Figure 5.11. Novo Nordisk: Financial Information
  • Figure 5.12. Roche: Financial Information
  • Figure 5.13. Takeda Pharmaceutical: Financial Information
  • Figure 6.1. Terminated Drugs: Distribution by Year of Discontinuation
  • Figure 6.2. Terminated Drugs: Distribution by Phase of Discontinuation
  • Figure 6.3. Terminated Drugs: Distribution by Mechanism of Action
  • Figure 6.4. Terminated Drugs: Distribution by Type of Indication
  • Figure 6.5. Terminated Drugs: Distribution by Reason for Termination
  • Figure 6.6. Terminated Drugs: Distribution by Affiliated Stakeholders
  • Figure 6.7. Terminated Drugs: Distribution by Study Start Year and Year of Termination of Clinical Trials
  • Figure 6.8. Terminated Drugs: Distribution by Location of Trials
  • Figure 7.1. Publication Analysis: Distribution by Year of Publication
  • Figure 7.2. Publication Analysis: Distribution by Key Focus Area
  • Figure 7.3. Publication Analysis: Word Cloud of Study Titles
  • Figure 7.4. Top Journals: Distribution by Number of Publications
  • Figure 7.5. Top Authors: Distribution by Number of Publications
  • Figure 8.1. Partnerships and Collaborations: Distribution by Year of Partnership
  • Figure 8.2. Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 8.3. Partnerships and Collaborations: Distribution by Type of Partnership and Focus Area of Partnership
  • Figure 8.4. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Molecule
  • Figure 8.5. Most Active Players: Distribution by Number of Partnerships
  • Figure 8.6. Partnerships and Collaborations: Regional Distribution
  • Figure 8.7. Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 9.1. Funding and Investment Analysis: Distribution by Year of Investment
  • Figure 9.2. Funding and Investment Analysis: Distribution by Amount Invested
  • Figure 9.3. Funding and Investment Analysis: Distribution by Type of Funding
  • Figure 9.4. Funding and Investment Analysis: Distribution by Amount Invested Across Different Types of Molecules
  • Figure 9.5. Funding and Investment Analysis: Distribution by Amount Invested Across Different Types of Mechanism of Action
  • Figure 9.6. Funding and Investment Analysis: Regional Distribution by Amount Invested
  • Figure 9.7. Most Active Players: Distribution by Number of Funding Instances
  • Figure 9.8. Most Active Investors: Distribution by Amount Funded
  • Figure 10.1. Grant Analysis: Distribution by Year of Grant Award
  • Figure 10.2. Grant Analysis: Distribution by Grant Amount Awarded
  • Figure 10.3. Grant Analysis: Distribution by Administering Institute Center
  • Figure 10.4. Grant Analysis: Distribution by Support Period
  • Figure 10.5. Grant Analysis: Distribution by Administering Institute Center and Support Year
  • Figure 10.6. Grant Analysis: Distribution by Type of Grant Application
  • Figure 10.7. Grant Analysis: Distribution by Grant Activity Code
  • Figure 10.8. Grant Analysis: Word Cloud of Study Titles
  • Figure 10.9. Grant Analysis: Distribution by Purpose of Grant Award
  • Figure 10.10. Grant Analysis: Distribution by Type of Recipient Organization
  • Figure 10.11. Popular NIH Departments: Distribution by Number of Grants
  • Figure 10.12. Prominent Program Officers: Distribution by Number of Grants
  • Figure 11.1. Clinical Trial Analysis: Distribution by Trial Status
  • Figure 11.2. Clinical Trial Analysis: Distribution by Trial Registration Year
  • Figure 11.3. Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 11.4. Clinical Trial Analysis: Distribution by Type of Study Design
  • Figure 11.5. Clinical Trial Analysis: Distribution by Registration Year and Type of Study
  • Figure 11.6. Clinical Trial Analysis: Distribution by Patient Enrollment
  • Figure 11.7. Clinical Trial Analysis: Year-wise Trend of Completed and Recruiting Trials
  • Figure 11.8. Clinical Trial Analysis: Distribution by Age Category
  • Figure 11.9. Clinical Trial Analysis: Word Cloud of Study Titles
  • Figure 11.10. Most Active Industry Players: Distribution by Number of Registered Trials
  • Figure 11.11. Most Active Non-Industry Players: Distribution by Number of Registered Trials
  • Figure 11.12. Clinical Trial Analysis: Distribution by Trial Location
  • Figure 11.13. Clinical Trial Analysis: Distribution by Trial Status and Geography
  • Figure 12.1. Patent Analysis: Distribution by Patent Application Year
  • Figure 12.2. Patent Analysis: Distribution by Geography
  • Figure 12.3. Patent Analysis: Distribution by CPC Symbols
  • Figure 12.4. Word Cloud: Emerging Focus Areas
  • Figure 12.5. Patent Analysis: Distribution by Type of Applicant
  • Figure 12.6. Leading Players: Distribution by Number of Patents
  • Figure 12.7 Leading Players: Distribution by Number of International Patents
  • Figure 12.8. Patent Analysis: Patent Valuation Analysis
  • Figure 13.1. Non-Pharmacological Interventions for Alzheimer's Disease
  • Figure 13.2. Cognition / Emotion-Oriented Interventions
  • Figure 13.3. Reminiscence Therapy
  • Figure 13.4. Simulated Presence Therapy
  • Figure 13.5. Sensory Stimulation-based Interventions
  • Figure 13.6. Virtual Reality
  • Figure 13.7. Music Therapy
  • Figure 13.8. Light Therapy
  • Figure 13.9. Aromatherapy
  • Figure 13.10. Reflexology
  • Figure 13.11. Other Psycho-social Interventions
  • Figure 13.12. Animal-Assisted Therapy
  • Figure 14.1. Global Alzheimer's Disease Market, 2021-2030 (USD Million)
  • Figure 14.2. Global Alzheimer's Disease Market, 2021-2030: Distribution by Type of Treatment (USD Million)
  • Figure 14.3. Global Alzheimer's Disease Market, 2021-2030: Distribution by Type of Target Disease Indication (USD Million)
  • Figure 14.4. Global Alzheimer's Disease Market, 2021-2030: Distribution by Geography (USD Million)
  • Figure 14.5. Alzheimer's Disease Market in North America, 2021-2030 (USD Million)
  • Figure 14.6. Alzheimer's Disease Market in North America, 2021-2030: Distribution by Type of Treatment (USD Million)
  • Figure 14.7. Alzheimer's Disease Market in North America, 2021-2030: Distribution by Symptomatic Treatment (USD Million)
  • Figure 14.8. Alzheimer's Disease Market in North America, 2021-2030: Share of Dementia in Symptomatic Treatment Market (USD Million)
  • Figure 14.9. Alzheimer's Disease Market in North America, 2021-2030: Share of Insomnia in Symptomatic Treatment Market (USD Million)
  • Figure 14.10. Alzheimer's Disease Market in North America, 2021-2030: Share of Other Psychological Symptoms in Symptomatic Treatment Market (USD Million)
  • Figure 14.11. Alzheimer's Disease Market in North America, 2021-2030: Distribution by Disease Modifying Treatment (USD Million)
  • Figure 14.12. Alzheimer's Disease Market in Europe, 2021-2030 (USD Million)
  • Figure 14.13. Alzheimer's Disease Market in Europe, 2021-2030: Distribution by Type of Treatment (USD Million)
  • Figure 14.14. Alzheimer's Disease Market in Europe, 2021-2030: Distribution by Symptomatic Treatment (USD Million)
  • Figure 14.15. Alzheimer's Disease Market in Europe, 2021-2030: Share of Dementia in Symptomatic Treatment Market (USD Million)
  • Figure 14.16. Alzheimer's Disease Market in Europe, 2021-2030: Share of Insomnia in Symptomatic Treatment Market (USD Million)
  • Figure 14.17. Alzheimer's Disease Market in Europe, 2021-2030: Share of Other Psychological Symptoms in Symptomatic Treatment Market (USD Million)
  • Figure 14.18. Alzheimer's Disease Market in Europe, 2021-2030: Distribution by Disease Modifying Treatment (USD Million)
  • Figure 14.19. Alzheimer's Disease Market in Asia-Pacific, 2021-2030(USD Million)
  • Figure 14.20. Alzheimer's Disease Market in Asia-Pacific, 2021-2030: Distribution by Type of Treatment (USD Million)
  • Figure 14.21. Alzheimer's Disease Market in Asia-Pacific, 2021-2030: Distribution by Symptomatic Treatment (USD Million)
  • Figure 14.22. Alzheimer's Disease Market in Asia-Pacific, 2021-2030: Share of Dementia in Symptomatic Treatment (USD Million)
  • Figure 14.23. Alzheimer's Disease Market in Asia-Pacific, 2021-2030: Share of Insomnia in Symptomatic Treatment (USD Million)
  • Figure 14.24. Alzheimer's Disease Market in Asia-Pacific, 2021-2030: Share of Other Psychological Symptoms in Symptomatic Treatment (USD Million)
  • Figure 14.25. Alzheimer's Disease Market in Asia-Pacific, 2021-2030: Distribution by Disease Modifying Treatment (USD Million)

List Of Tables

  • Table 4.1 Alzheimer's Disease: Marketed and Clinical Development Pipeline
  • Table 4.2 Alzheimer's Disease Therapies: List of Developers
  • Table 6.1 Alzheimer's Disease Therapies: List of Terminated Drugs
  • Table 7.1 Alzheimer's Disease: List of Publications
  • Table 8.1 Alzheimer's Disease: List of Partnerships and Collaborations
  • Table 9.1 Alzheimer's Disease: List of Funding and Investments
  • Table 10.1 Alzheimer's Disease: List of Academic Grants
  • Table 11.1 Alzheimer's Disease: List of Clinical Trials
  • Table 12.1 Alzheimer's Disease: List of Patents

List Of Companies

The following companies and organizations have been mentioned in the report.

  • 1. AB Science
  • 2. AbbVie
  • 3. AC Immune
  • 4. ACADIA Pharmaceuticals
  • 5. Acelot
  • 6. Actinogen Medical
  • 7. Acumen Pharmaceuticals
  • 8. AFFiRiS
  • 9. AgeneBio
  • 10. Alector
  • 11. Alkahest
  • 12. Allergan (part of AbbVie)
  • 13. Allinky Biopharma
  • 14. Alterity Therapeutics (formerly known as Prana Biotechnology)
  • 15. Alzheimer's Association
  • 16. Alzheimer's Disease Cooperative Study (ADCS)
  • 17. Alzinova
  • 18. Alzprotect
  • 19. American Life Science Pharmaceuticals (ALSP)
  • 20. Amylyx Pharmaceuticals
  • 21. Anavex Life Sciences
  • 22. Aphios
  • 23. APRINOIA Therapeutics
  • 24. Archer Pharmaceuticals
  • 25. Ariana Pharma
  • 26. AriBio
  • 27. ArmaGen (acquired by JCR Pharmaceuticals)
  • 28. ARMGO Pharma
  • 29. Asceneuron
  • 30. AstraZeneca
  • 31. Athira Pharma (formerly known as M3 Biotechnology)
  • 32. Atridia
  • 33. Ausio Pharmaceuticals
  • 34. Autifony Therapeutics
  • 35. Avanir Pharmaceuticals
  • 36. Avid Radiopharmaceuticals
  • 37. Axon Neuroscience
  • 38. Axsome Therapeutics
  • 39. AZTherapies
  • 40. Banner Alzheimer's Institute
  • 41. Bausch Health
  • 42. Beacon Biosignals
  • 43. BELLUS Health
  • 44. BioArctic
  • 45. Biogen
  • 46. Biohaven
  • 47. Bionomics
  • 48. BioVie
  • 49. Bristol Myers Squibb
  • 50. Cambridge Quantum Computing (CQC)
  • 51. Cassava Sciences (formerly known as Pain Therapeutics)
  • 52. Celgene
  • 53. Cenna Biosciences
  • 54. CEOi
  • 55. Cerecin (formerly Accera)
  • 56. CereSpir
  • 57. CHA Biotech
  • 58. Chang Gung Memorial Hospital (CGMH)
  • 59. Changchun Huayang High-tech
  • 60. Chaperone Therapeutics
  • 61. Charsire Biotechnology
  • 62. Cogentis Therapeutics
  • 63. Cognition Therapeutics
  • 64. Cognosci
  • 65. CoMentis
  • 66. Corium International
  • 67. Cortexyme
  • 68. CuraSen Therapeutics
  • 69. Cure Alzheimer's Fund
  • 70. Cure Network Dolby Acceleration Partners (CNDAP)
  • 71. Cyclerion Therapeutics
  • 72. DAE HWA Pharmaceutical
  • 73. Denali Therapeutics
  • 74. Denovo Biopharma
  • 75. Edunn Biotechnology
  • 76. EIP Pharma
  • 77. Eisai
  • 78. Eli Lilly
  • 79. E-Scape Bio
  • 80. Evidation
  • 81. ExonHit Therapeutics (part of Sofinnova Partners)
  • 82. FUJIFILM Toyama Chemical
  • 83. GemVax & Kael
  • 84. Genentech
  • 85. Genervon Biopharmaceuticals
  • 86. Genzyme
  • 87. Gismo Therapeutics
  • 88. GlaxoSmithKline
  • 89. GliaCure
  • 90. GliaPharm
  • 91. Grifols
  • 92. HSRx Biopharmaceutical
  • 93. Hyundai Pharm
  • 94. IlDong Pharmaceutical
  • 95. Imeka
  • 96. INmune Bio
  • 97. Innovative California Biosciences International
  • 98. IntelGenx
  • 99. Intellect Neurosciences
  • 100. Intra-Cellular Therapies
  • 101. Ionis Pharmaceuticals
  • 102. IXICO
  • 103. Janssen Pharmaceuticals
  • 104. Johns Hopkins University
  • 105. KalGene Pharmaceuticals
  • 106. Karuna Pharmaceuticals
  • 107. Konkuk University Medical Center (KUMC)
  • 108. K-PAX Pharmaceuticals
  • 109. Kyowa Hakko Kirin
  • 110. Libella Gene Therapeutics
  • 111. Lipopharma
  • 112. Longeveron
  • 113. Lundbeck
  • 114. Lyndra Therapeutics
  • 115. MD Anderson Cancer Center
  • 116. Medesis Pharma
  • 117. Medipost
  • 118. Medpace
  • 119. Merck Sharp & Dohme
  • 120. Metabolic Solutions Development.
  • 121. Mission Therapeutics
  • 122. Mylan
  • 123. National Institute of Mental Health (NIMH)
  • 124. National Institute on Aging (NIA)
  • 125. National Institutes of Health (NIH)
  • 126. National Research Council Canada
  • 127. Nature Cell
  • 128. Neuralstem
  • 129. Neurim Pharmaceuticals
  • 130. NeuroActiva
  • 131. Neurocentria
  • 132. Neurodon
  • 133. NeuroGeneration
  • 134. NeuroGenetic Pharmaceuticals
  • 135. NeuroNascent
  • 136. NeurOp
  • 137. Neurotez
  • 138. NIH Clinical Center (CC)
  • 139. Novartis
  • 140. Novo Nordisk
  • 141. NYU Langone Health
  • 142. Orion Pharma
  • 143. Oryzon Genomics
  • 144. Otsuka Pharmaceutical
  • 145. P2D Bioscience
  • 146. Pfizer
  • 147. PharmatrophiX
  • 148. Pharmazz
  • 149. Pharnext
  • 150. Proclara Biosciences
  • 151. Procter & Gamble
  • 152. ProMIS Neurosciences
  • 153. Prothena
  • 154. QR Pharma
  • 155. Regenera Pharma
  • 156. RemeGenix
  • 157. ReMYND
  • 158. Reviva Pharmaceuticals
  • 159. Roche
  • 160. Sage Therapeutics
  • 161. Sahlgrenska University Hospital
  • 162. Sangamo Therapeutics
  • 163. Sanofi
  • 164. Selexis
  • 165. Shahid Sadoughi University of Medical Sciences and Health Services
  • 166. Shanghai Green Valley Pharmaceutical
  • 167. Shape Therapeutics
  • 168. Shionogi
  • 169. Sierra Sciences
  • 170. Sosei Heptares
  • 171. St Vincent's Institute of Medical Research (SVI)
  • 172. Stemedica Cell Technologies
  • 173. Suven Life Sciences
  • 174. Synaptogenix (formerly Neurotrope Bioscience)
  • 175. T3D Therapeutics
  • 176. Taipei Veterans General Hospital (TVGH)
  • 177. Taiyo International
  • 178. Takeda Pharmaceutical
  • 179. TauRx Therapeutics
  • 180. Tetra Discovery Partners
  • 181. THERANEXUS
  • 182. Tonix Pharmaceuticals
  • 183. Treventis
  • 184. TrueBinding
  • 185. UCB
  • 186. University of California
  • 187. University of Kansas Medical Center (KUMC)
  • 188. University of Oslo
  • 189. University of Texas
  • 190. VA Office of Research and Development (ORD)
  • 191. Vaccinex
  • 192. Vaxxinity (formerly known as United Neuroscience)
  • 193. Vivoryon Therapeutics (formerly Probiodrug)
  • 194. Voyager Therapeutics
  • 195. VT BIO
  • 196. Worldwide Clinical Trials
  • 197. Wyeth
  • 198. Xcelthera